Aldeyra The (ALDX) Stock Analysis & Winston Score

Aldeyra Therapeutics is a small biotech company focused on developing drugs that treat inflammatory diseases and certain rare conditions. Its main drug candidate, reproxalap, targets dry eye disease — a condition where the eyes don't produce enough moisture, causing pain and irritation. The company sells to patients and works through the healthcare system, including doctors and pharmacies. Aldeyra makes money by developing and eventually selling prescription drugs, though as of its most recent reported periods it had no meaningful product revenue and was still spending heavily on clinical trials and regulatory approvals. It operates primarily in the United States and has a market cap of roughly $100 million, making it a very small company in the biotech space. The biggest risk it faces is that its pipeline depends heavily on regulatory approval from the FDA — if key drug candidates fail in trials or are rejected, the company has limited other revenue sources to fall back on.